undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp balance sheet

At the end of fiscal 2025, Bionexus Gene Lab Corp had total assets of $9.3m, total liabilities of $637,856 and shareholders' equity of $8.6m. It held $2.4m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents113225321
Receivables——————110
Inventory001211111
Total current assets118768755
Total assets2110109111099
Accounts payable———2212——
Total current liabilities003222211
Total debt000000000
Total liabilities003222211
Shareholders' equity2177710898
Shares outstanding———171m14m18m18m2m2m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BGLC vs QSIBGLC vs SEERBGLC vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionexus Gene Lab Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionexus Gene Lab Corp.